**Author details**

Kourosh Rezania1 \* and Laleh Saadat<sup>2</sup>

1 Department of Neurology, University of Chicago Medical Center, Chicago, IL, USA

2 Department of Surgery, University of Chicago Medical Center, Chicago, IL, USA

\*Address all correspondence to: krezania@neurology.bsd.uchicago.edu

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**103**

*Neurological Manifestations of Transthyretin-Related Amyloidosis*

molecular imaging and therapy. Journal of Internal Medicine.

[9] Plante-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, et al. Diagnostic pitfalls in sporadic transthyretin familial amyloid

polyneuropathy (TTR-FAP). Neurology.

[11] Schmidt HH, Waddington-Cruz M, Botteman MF, Carter JA, Chopra AS, Hopps M, et al. Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle &

[12] Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet Journal of Rare Diseases.

[13] Adams D, Theaudin M, Cauquil C,

neuropathy and emerging treatments. Current Neurology and Neuroscience

[14] Holmgren G, Costa PM, Andersson C, Asplund K, Steen L, Beckman L, et al. Geographical distribution of TTR met30 carriers in northern Sweden: Discrepancy between carrier frequency and prevalence rate. Journal of Medical

Algalarrondo V, Slama M. FAP

Genetics. 1994;**31**(5):351-354

[15] Sousa A, Coelho T, Barros J, Sequeiros J. Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and

Reports. 2014;**14**(3):435

[10] Sekijima Y, Ueda M, Koike H, Misawa S, Ishii T, Ando Y. Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: Redflag symptom clusters and treatment algorithm. Orphanet Journal of Rare

2018;**283**(3):218-237

2007;**69**(7):693-698

Diseases. 2018;**13**(1):6

Nerve. 2018;**57**(5):829-837

2013;**8**:31

*DOI: http://dx.doi.org/10.5772/intechopen.84470*

[1] Lachmann HJ, Hawkins PN. Systemic

[2] Sipe JD, Benson MD, Buxbaum JN, Ikeda SI, Merlini G, Saraiva MJ, et al. Amyloid fibril proteins and amyloidosis: Chemical identification and clinical classification International

Nomenclature Guidelines. Amyloid.

[3] Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016;**387**(10038):2641-2654

[4] Wallace MR, Naylor SL, Kluve-Beckerman B, Long GL, McDonald L, Shows TB, et al. Localization of the human prealbumin gene to chromosome 18. Biochemical and Biophysical Research Communications.

[5] Episkopou V, Maeda S, Nishiguchi S,

[6] Palha JA. Transthyretin as a thyroid hormone carrier: Function revisited. Clinical Chemistry and Laboratory Medicine. 2002;**40**(12):1292-1300

[7] Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: Unravelling the impact of transthyretin amyloid fibril composition. Journal of Internal Medicine. 2017;**281**(4):337-347

[8] Fandrich M, Nystrom S, Nilsson KPR, Bockmann A, LeVine H, 3rd, Hammarstrom P. Amyloid fibril polymorphism: A challenge for

Gottesman ME, et al. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid hormone. Proceedings of the National Academy of Sciences of the United States of America.

amyloidosis. Current Opinion in Pharmacology. 2006;**6**(2):214-220

Society of Amyloidosis 2016

2016;**23**(4):209-213

1985;**129**(3):753-758

1993;**90**(6):2375-2379

Shimada K, Gaitanaris GA,

**References**

*Neurological Manifestations of Transthyretin-Related Amyloidosis DOI: http://dx.doi.org/10.5772/intechopen.84470*
